<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Immunology Product Guide &#187; Vaxfectin(R) adjuvant</title>
	<atom:link href="http://www.immunologyproductguide.com/blog/tag/vaxfectinr-adjuvant/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.immunologyproductguide.com/blog</link>
	<description>A comprehensive guide to immunology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 10:09:04 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Vical Advocates DNA Vaccine Approach With Pandemic Influenza Experts</title>
		<link>http://www.immunologyproductguide.com/blog/2009/12/16/vical-advocates-dna-vaccine-approach-with-pandemic-influenza-experts/</link>
		<comments>http://www.immunologyproductguide.com/blog/2009/12/16/vical-advocates-dna-vaccine-approach-with-pandemic-influenza-experts/#comments</comments>
		<pubDate>Wed, 16 Dec 2009 11:32:58 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Vaccination]]></category>
		<category><![CDATA[influenza]]></category>
		<category><![CDATA[DNA vaccine technology]]></category>
		<category><![CDATA[influenza vaccine]]></category>
		<category><![CDATA[Vaxfectin(R) adjuvant]]></category>
		<category><![CDATA[Vical Incorporated]]></category>

		<guid isPermaLink="false">http://www.immunologyproductguide.com/blog/?p=201</guid>
		<description><![CDATA[Vical Incorporated has announced that the company addressed an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company&#8217;s DNA vaccine technology and Vaxfectin(R) adjuvant. DNA vaccines can be developed and produced very quickly using scaleable manufacturing processes which are not dependent upon chicken eggs or other [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.immunologyproductguide.com/blog/wp-content/uploads/2009/12/Vical-Advocates.png"><img class="alignleft size-full wp-image-202" style="margin: 5px" src="http://www.immunologyproductguide.com/blog/wp-content/uploads/2009/12/Vical-Advocates.png" border="0" alt="Vical Advocates" width="200" height="81" /></a>Vical Incorporated has announced that the company addressed an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company&#8217;s DNA vaccine technology and Vaxfectin(R) adjuvant. DNA vaccines can be developed and produced very quickly using scaleable manufacturing processes which are not dependent upon chicken eggs or other cell culture methods.</p>
<p>For the full story, <a href="http://money.cnn.com/news/newsfeeds/articles/globenewswire/179914.htm" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.immunologyproductguide.com/blog/2009/12/16/vical-advocates-dna-vaccine-approach-with-pandemic-influenza-experts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
